Tags

Type your tag names separated by a space and hit enter

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.

Abstract

Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provide long-acting muscarinic antagonist (glycopyrronium bromide), long-acting beta agonist (indacaterol), and a combination of the two medications (QVA149). The choice among the three medications allows a patient to use the same inhalation device even when the regimen is changed from single-bronchodilator therapy to dual-bronchodilator therapy. In addition, the quick bronchodilation effect and once-daily administration can improve patient adherence to medical treatment for chronic obstructive pulmonary disease (COPD). To our knowledge, as of November 2014, the safety and the efficacy of QVA149 have been evaluated in 14 randomized controlled trials. The 14 trials generally showed good safety profiles, and there were better or not-inferior bronchodilator effects of QVA149 when compared with placebo, or other inhaled medication. According to the Japanese Respiratory Society guidelines, QVA149 is a combination of the two first-line bronchodilators. Our meta-analysis indicated that QVA149 is superior to the salmeterol-fluticasone combination to treat COPD in respect of the frequency of adverse effects, exacerbation, pneumonia, and improvement of trough forced expiratory volume in 1 second (FEV1). Thus, we believe that QVA149 can be a key medication for COPD treatments.

Authors+Show Affiliations

Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

25960646

Citation

Horita, Nobuyuki, and Takeshi Kaneko. "Role of Combined Indacaterol and Glycopyrronium Bromide (QVA149) for the Treatment of COPD in Japan." International Journal of Chronic Obstructive Pulmonary Disease, vol. 10, 2015, pp. 813-22.
Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2015;10:813-22.
Horita, N., & Kaneko, T. (2015). Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. International Journal of Chronic Obstructive Pulmonary Disease, 10, 813-22. https://doi.org/10.2147/COPD.S56067
Horita N, Kaneko T. Role of Combined Indacaterol and Glycopyrronium Bromide (QVA149) for the Treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2015;10:813-22. PubMed PMID: 25960646.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. AU - Horita,Nobuyuki, AU - Kaneko,Takeshi, Y1 - 2015/04/21/ PY - 2015/5/12/entrez PY - 2015/5/12/pubmed PY - 2016/2/5/medline KW - bronchodilator agents KW - delivery of health care KW - dry powder inhalers KW - guideline KW - meta-analysis KW - muscarinic antagonists SP - 813 EP - 22 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 10 N2 - Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provide long-acting muscarinic antagonist (glycopyrronium bromide), long-acting beta agonist (indacaterol), and a combination of the two medications (QVA149). The choice among the three medications allows a patient to use the same inhalation device even when the regimen is changed from single-bronchodilator therapy to dual-bronchodilator therapy. In addition, the quick bronchodilation effect and once-daily administration can improve patient adherence to medical treatment for chronic obstructive pulmonary disease (COPD). To our knowledge, as of November 2014, the safety and the efficacy of QVA149 have been evaluated in 14 randomized controlled trials. The 14 trials generally showed good safety profiles, and there were better or not-inferior bronchodilator effects of QVA149 when compared with placebo, or other inhaled medication. According to the Japanese Respiratory Society guidelines, QVA149 is a combination of the two first-line bronchodilators. Our meta-analysis indicated that QVA149 is superior to the salmeterol-fluticasone combination to treat COPD in respect of the frequency of adverse effects, exacerbation, pneumonia, and improvement of trough forced expiratory volume in 1 second (FEV1). Thus, we believe that QVA149 can be a key medication for COPD treatments. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/25960646/Role_of_combined_indacaterol_and_glycopyrronium_bromide__QVA149__for_the_treatment_of_COPD_in_Japan_ L2 - https://dx.doi.org/10.2147/COPD.S56067 DB - PRIME DP - Unbound Medicine ER -